

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

Effective Date:	4/1/2023
------------------------	-----------------

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)
[APPENDIX](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Genetic testing for alpha1-antitrypsin (AAT) deficiency may be considered **medically necessary** when either of the following conditions are met:

1. Member is suspected of having alpha1-antitrypsin deficiency because of clinical factors and/or because the patient may be at high risk of having alpha1-antitrypsin deficiency due to a first-degree relative with AAT deficiency (see Policy Guidelines); **or**
2. Member has a serum alpha-₁ antitrypsin level in the range of severe deficiency (see Policy Guidelines).

Genetic testing for alpha₁-antitrypsin deficiency is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this testing.

Policy Guidelines

According to the 2003 joint statement on diagnosis and management of alpha-₁ antitrypsin deficiency by the American Thoracic Society/European Respiratory Society. The following features should prompt suspicion by physicians that their patient may be more likely to have AAT deficiency:

Clinical factors

- Early-onset emphysema (age of 45 years or less)
- Emphysema in the absence of a recognized risk factor (smoking, occupational dust exposure, etc.)
- Emphysema with prominent basilar hyperlucency
- Otherwise, unexplained liver disease
- Necrotizing panniculitis
- Anti-proteinase 3-positive vasculitis (C-ANCA [anti-neutrophil cytoplasmic antibody]-positive vasculitis)
- Bronchiectasis without evident etiology

Family history

- A first-degree relative is defined as a parent, child or sibling.

Table PG1 shows the range of serum levels of alpha1-antitrypsin by common phenotypes according to the commercial standard milligram per deciliter and the purified standard micromole. A level less than 11 μmol is generally considered to be associated with an increased risk of clinical disease, but this cutoff may vary according to the specific test used (American

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

Thoracic Society & European Respiratory Society, 2003; Global Initiative for Chronic Obstructive Lung Disease, 2016).

Table PG1. Range of Alpha1-Antitrypsin Serum Levels by Common Phenotypes

	MM	MZ	SS	SZ	ZZ	Znull	Null-Null
Mmol	20-48	17-33	15-33	8-16	2.5-7	<2.5	0
mg/dL	150-350	90-210	100-200	75-120	20-45	<20	0

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG2). The Society’s nomenclature is recommended by the Human Variome Project, the HUMAN Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG3 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

Table PG2. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG3. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO:

Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

Alpha₁-Antitrypsin Deficiency

Alpha₁-antitrypsin deficiency (AATD) is an autosomal recessive genetic disorder that decreases the production of functional alpha₁-antitrypsin (AAT) protein or results in production of abnormal types of the protein that are functionally deficient. Data from screening studies have found the prevalence of AATD in the United States to be between 1 in 2857 and 1 in 5097 individuals.

AAT is an acute phase glycoprotein, primarily synthesized in the liver and secreted into the bloodstream. One of the primary functions of the AAT protein is to protect the lungs from damage by the enzyme elastase. Elastase, part of the normal response to injury and inflammation, breaks down proteins and can damage lung tissue if its action is not regulated by AAT. Individuals with AATD thus have an increased risk of lung disease.

AATD Genetics

Production of AAT is encoded by the *SERPINA1* gene, which is codominant (each gene copy is responsible for producing half of the AAT). Although there are more than 75 sequence variants of the *SERPINA1* gene (i.e., 75 possible alleles), only a few are common in North America. Approximately 95% of individuals have 2 copies of the normal M allele sequence (MM) and have mean serum AAT concentrations ranging from 20 to 53 µmol/L. The most common abnormal forms are the Z and the S alleles. Individuals with 2 copies of the Z allele (ZZ) tend to be most severely affected, with mean serum AAT concentrations of 2.5 to 7 µmol/L and a high risk of chronic obstructive pulmonary disease. Individuals with genotype SS and heterozygous

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

Individuals with genotype MZ have a low risk of chronic obstructive pulmonary disease and moderately lower levels of AAT. Individuals with rarer pathogenic variants of the *SERPINA1* gene or null alleles may not produce any AAT and are also at high risk.

Clinical Presentation

AATD is a multisystem disease, primarily affecting the lungs and liver, and less commonly the skin. It may present differently at different ages.

Pulmonary Manifestations

Respiratory disease tends to be more severe and occur sooner (i.e., between ages 40 and 50 years) in individuals with AATD who smoke cigarettes and/or are exposed to occupational dust or fumes. In nonsmokers and individuals without environmental exposure, the onset of respiratory disease occurs more commonly in the sixth decade. Childhood-onset lung disease is rare with AATD.

Liver Manifestations

Adults with AATD-associated liver disease generally present with cirrhosis and fibrosis. In contrast, newborns with AATD can present with cholestasis or (less frequently) hepatomegaly and elevated aminotransferase levels. The AATD-associated cholestasis is typically associated with PI*Z homozygotes or PI*SZ heterozygotes, which tend to have less severe lung disease in adulthood. AATD-associated-cholestatic jaundice can progress to require a liver transplant in newborns. In a large series (1976) of 127 newborns with AATD found by screening, the prevalence of liver damage was 11%, severe in about two-thirds of cases.

Skin Manifestations

Panniculitis is a rare, but well-recognized complication of AATD. This dermatologic condition is characterized by inflammatory and necrotizing lesions of the skin and subcutaneous tissue.

Clinical Management

The primary interventions to prevent or treat lung-related symptoms in adults with AATD involve behavioral change, especially avoiding or quitting cigarette smoking. Smoking is the most important risk factor for the development of emphysema in AATD in individuals who are homozygous for the most severe AAT pathogenic variants. In addition, individuals with AATD are advised to avoid other substances that can irritate the lungs (e.g., cigarette smoke, dust, workplace chemicals), as well as substances that can cause liver damage (e.g., alcohol). There are also general recommendations to exercise, avoid stress, and have a nutritious diet. Furthermore, patients with AATD may be recommended to have earlier or more aggressive treatments for conditions such as asthma outbreaks or acute exacerbations of chronic obstructive pulmonary disease. One treatment option that is specific to AATD is AAT augmentation. There are commercially available intravenous AAT augmentation products; patients generally receive injections of plasma every 3 to 4 weeks for life. Inhaled AAT augmentation therapy is under development. There is no consensus on the efficacy of augmentation treatment. Product labels state that the effect of augmentation therapy on emphysema progression and pulmonary exacerbations has not been demonstrated in randomized controlled trials.

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

Other aspects of AATD management involve monitoring for and screening for comorbidities, including liver disease.

Diagnostic Testing for AAT

Several types of tests are available for patients suspected of having AATD. A blood test is available that quantifies the total amount of AAT in the blood, detecting decreases in AAT protein levels, but not distinguishing among abnormal protein types. AAT is an acute phase reactant, and levels will be elevated in acute and chronic inflammatory conditions, infections, and some cancers, which may cause levels to appear normal in individuals with mild-to-moderate AATD. In general, a serum AAT concentration less than 15% to 20% of the normal value is highly suggestive of a homozygous AAT pathogenic variant.

The alpha₁ phenotype test identifies the type of circulating AAT protein in the blood by isoelectric focusing of the various AAT protein types. Patterns of protein migration in an electric field are evaluated and compared with normal patterns to determine if and what type of abnormal AAT protein may be present.

Genetic testing for AATD can be done with the alpha₁ genotype test. This test uses polymerase chain reaction analysis or nucleic acid-based analysis to identify abnormal alleles of AAT DNA. Currently, available genotype tests are only designed to detect the most common pathogenic variants (i.e., S and Z alleles).

There are several testing approaches to detect AATD. One is to initially perform serum quantitation, and then, if the AAT level is found to be low, a follow-up phenotype or genotype test is ordered. Another approach is to perform serum protein quantification, followed by genotype testing in subjects with clinical suspicion of AATD. If these tests are discordant, phenotype testing is then performed.

Regulatory Status

In 2007, the phenotyping test Hydragel 18 A1AT ISOFOCUSING kit (Sebia, GA) was cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for the qualitative detection and identification of the phenotypes of AAT protein. Food and Drug Administration product code: OBZ.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the Food and Drug Administration has chosen not to require any regulatory review of this test.

IV. RATIONALE

[TOP](#)

Summary of Evidence

For individuals who have suspected AATD who receive genetic testing for AATD, the evidence includes studies on clinical validity, and several controlled studies assessing potential clinical utility. Relevant outcomes are test accuracy and validity, symptoms, and morbid events. Genetic testing can confirm a diagnosis of AATD suggested by serum testing by identifying the known genetic variants associated with the disease and identify AATD when a diagnosis is uncertain

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

due to the suspicious clinical presentation that is not confirmed by serum testing. A chain of evidence suggests that making a diagnosis of AATD in individuals with suspected AATD can support clinical utility by allowing monitoring for multisystem complications and initiation of accepted therapies. Knowledge of AATD status may lead to behavior changes or changes in medical management that lead to improved health outcomes; however, there is limited supportive evidence. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

N/A

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

Procedure Codes								
G0452	81332							

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

ICD-10-CM Diagnosis Code	Description
E88.01	Alpha1-antitrypsin deficiency

IX. REFERENCES

[TOP](#)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med.* Oct 01, 2003;168(7):818-900. PMID 14522813
2. Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. *Respir Med.* Jun 2010;104(6):763-772. PMID 20303723
3. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. *N Engl J Med.* Jun 10, 1976;294(24):1316-1321. PMID 1083485
4. Stoller JK, Lachawan FL, Aboussouan LS. Alpha-1 antitrypsin deficiency. In: Adam M, Ardinger H, Pagon R, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2017.
5. CSL Behring LLC. Zemaira, Alpha1-Proteinase Inhibitor (Human): Package Insert. 2015 Sept
6. Baxter Healthcare Corp. GLASSIA (Alpha1-Proteinase Inhibitor (Human)): Package Insert. 2010 Aug.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). *Global Strategy for Diagnosis, Management, and Prevention of COPD 2016*. 2016
8. Food and Drug Administration (FDA). 510(k) substantial equivalence determination decision summary (K063498). n.d.
9. Greulich T, Averyanov A, Borsa L, et al. European screening for alpha1 -antitrypsin deficiency in subjects with lung disease. *Clin Respir J.* Jan 2017;11(1):90-97. PMID 25919395
10. Sorroche PB, Fernandez Acquier M, Lopez Jove O, et al. Alpha-1 antitrypsin deficiency in COPD patients: a cross-sectional study. *Arch Bronconeumol.* Nov 2015;51(11):539-543. PMID 25800328
11. Ljujic M, Topic A, Divac A, et al. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants. *Transl Res.* May 2008;151(5):255-259. PMID 18433707
12. Beletic A, Dudvarski-Ilic A, Milenkovic B, et al. Is an integrative laboratory algorithm more effective in detecting alpha-1-antitrypsin deficiency in patients with premature chronic obstructive pulmonary disease than AAT concentration-based screening approach? *Biochem Med (Zagreb).* Jun 2014;24(2):293-298. PMID 24969923
13. Lerman C, Gold K, Audrain J, et al. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. *Health Psychol.* Jan 1997;16(1):87-99. PMID 9028818
14. Audrain J, Boyd NR, Roth J, et al. Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. *Addict Behav.* Nov-Dec 1997;22(6):741-751. PMID 9426791

MEDICAL POLICY

POLICY TITLE	GENETIC TESTING FOR ALPHA1- ANTITRYPSIN DEFICIENCY
POLICY NUMBER	MP 2.251

15. Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. *Ann Behav Med.* Feb 2007;33(1):22-28. PMID 17291167
16. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev.* Sep 20, 2016;9:CD007851. PMID 27644166
17. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. *Am J Respir Crit Care Med.* Nov 1999;160(5 Pt 1):1468-1472. PMID 10556107
18. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. *Eur Respir J.* Jun 2009;33(6):1345-1353. PMID 19196813
19. Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet.* Jul 25, 2015;386(9991):360-368. PMID 26026936
20. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. *Can Respir J.* Mar-Apr 2012;19(2):109-116. PMID 22536580
21. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in 1-antitrypsin deficiency. *European Respiratory Journal.* 2017 Nov 1;50(5):1700610. PMID 29191952.
22. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ.* Jan 1997;75(5):397-415. PMID 9447774
23. Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.04.79, Genetic Testing for Alpha1-Antitrypsin Deficiency. February 2022.

X. POLICY HISTORY

[Top](#)

MP 2.251	4/6/2020 Minor review. Policy statement changed to now state “either” and “or” vs “both” and “and”. References updated.
	1/29/2021 Consensus review. No change to policy statement. References and coding review.
	6/16/2022 Consensus Review. No change to policy statement. References updated. Coding reviewed.
	1/5/2023 Consensus Review. No change to policy statement. References reviewed and updated.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.